Cambridge, United Kingdom

Cecilia Deantonio

USPTO Granted Patents = 3 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Work of Inventor Cecilia Deantonio

Introduction: Cecilia Deantonio is a renowned inventor based in Cambridge, GB, with a remarkable portfolio of three patents. Her work particularly focuses on the development of anti-PD-L1 antibodies and immunocytokines, contributing significantly to the field of biomedicine. Through her innovations, Deantonio aims to advance treatment options for various conditions by harnessing the power of the immune system.

Latest Patents: Among her latest patents, Cecilia Deantonio has developed groundbreaking inventions including anti-PD-L1 antibodies. These antibodies are designed to interconnect with specific domains, enhancing their efficacy in medical applications. She has also pioneered bispecific antibodies containing one domain with specificity to PD-L1, as well as immunocytokines that fuse anti-PD-L1 antibodies with cytokines like IL-2. Her patents encompass methods of treatment, various therapeutic uses, and pharmaceutical compositions, setting a new standard in immunotherapy.

Career Highlights: Deantonio’s current position at Kymab Limited highlights her dedication to advancing medical science through innovative research. Her experience and expertise have enabled her to create impactful inventions that hold promise for improving patient outcomes. The recognition received from her patents underlines her significant contributions to the field and the potential impact on health care.

Collaborations: Throughout her career, Cecilia has collaborated with esteemed colleagues, including Nikole Sandy and Cassandra Van Krinks. These partnerships have been instrumental in fostering an environment of innovation, enabling the development of their joint discoveries and further enhancing their research contributions.

Conclusion: Cecilia Deantonio exemplifies the spirit of innovation and dedication within the scientific community. Her work in developing anti-PD-L1 antibodies and their applications reflects her commitment to improving therapeutic options and advancing biomedical research. As her career continues to evolve, Deantonio remains a pivotal figure in the field of immunotherapy, inspiring future inventors and researchers alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…